Is Hepatic Cannabinoid 1 Receptor a Key Driver of Obesity? Implications of the Weight‐Reducing Efficacy of the Hepatotropic Inverse Agonist TM38837

Martin E. Cooper
Obesity Reviews · Wiley · 2026-11-10 · DOI: 10.1111/obr.70166

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles